Bundibugyo Virus Outbreak Response Vaccines (BundiVx)
The following award(s) were made under RRPV 26‑13-BundiVx. This BARDA-led rapid response initiative aims to accelerate development and readiness of vaccine candidates for Bundibugyo ebolavirus by leveraging established platform technologies; supported activities include manufacturing of cGMP Phase 1 clinical trial material, IND‑enabling nonclinical work, early clinical evaluation (Phase 1), regulatory engagement, and optional scale-up and outbreak-support activities to strengthen national health security and outbreak response capabilities.
Accelerating a VSV-Based Bundibugyo Virus Vaccine for Outbreak Response and Future Preparedness
Project Objective: The award supports manufacturing of vaccine doses for clinical evaluation and outbreak response, clinical and regulatory activities including a Phase 1 trial, and options for expanded manufacturing to support future preparedness needs, as well as development of an updated vaccine candidate based on the viral variant causing the 2026 Bundibugyo outbreak.
Project Details
Member Organization: International Aids Vaccine Initiative, Inc.
Award Date: 09/29/2026
Award Amount: $36,382,096
Project Duration: 48 Months
Solicitation Number: RPP-26-13-BundiVx